Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at TD Cowen

TD Cowen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a report released on Monday,Zacks.com reports.

Several other equities research analysts have also commented on MAZE. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Price Performance

MAZE opened at $29.60 on Monday. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -11.75 and a beta of 2.22. The business’s fifty day simple moving average is $28.42 and its 200-day simple moving average is $32.27. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics has a 12-month low of $12.91 and a 12-month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts anticipate that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total value of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 108,110 shares of company stock worth $3,057,531. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. California State Teachers Retirement System increased its position in Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $48,000. Finally, Ameritas Investment Partners Inc. grew its holdings in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.